$2.25 Billion is the total value of NEA Management Company, LLC's 43 reported holdings in Q1 2018. The portfolio turnover from Q4 2017 to Q1 2018 was 100.0% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| OREXQ | Exit | OREXIGEN THERAPEUTICS INC | $0 | – | -370,900 | -100.0% | -0.02% | – |
| ABIO | Exit | ARCA BIOPHARMA INC | $0 | – | -1,460,209 | -100.0% | -0.08% | – |
| CASC | Exit | CASCADIAN THERAPEUTICS INC | $0 | – | -9,064,575 | -100.0% | -1.39% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2018-05-10
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| GLYCOMIMETICS INC | 41 | Q1 2024 | 7.6% |
| AURINIA PHARMACEUTICALS INC | 40 | Q2 2024 | 5.0% |
| CHAMPIONS ONCOLOGY INC | 36 | Q2 2024 | 1.2% |
| LEXICON PHARMACEUTICALS INC | 35 | Q2 2024 | 2.0% |
| ADAPTIMMUNE THERAPEUTICS PLC | 34 | Q2 2024 | 9.3% |
| CRISPR THERAPEUTICS AG | 31 | Q2 2024 | 11.2% |
| TREVENA INC | 31 | Q3 2021 | 3.3% |
| AKARI THERAPEUTICS PLC | 31 | Q2 2023 | 0.3% |
| ARDELYX INC | 29 | Q3 2021 | 11.9% |
| VERONA PHARMA PLC | 29 | Q2 2024 | 9.0% |
View NEA Management Company, LLC's complete holdings history.
Latest filings
| Type | Filed |
|---|---|
| N-PX | 2024-08-30 |
| 13F-HR | 2024-08-14 |
| 13F-HR | 2024-05-15 |
| 13F-HR | 2024-02-14 |
| 13F-HR | 2023-11-14 |
| 13F-HR | 2023-08-11 |
| 13F-HR | 2023-05-15 |
| 13F-HR | 2023-02-10 |
| 13F-HR | 2022-11-14 |
| 13F-HR | 2022-08-15 |
View NEA Management Company, LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.